Thursday, December 08, 2016 9:11:35 PM
A relatively worst case scenario (but not really) would be Merck only paying for the cost of Keytruda. Still not bad if ONCS can get good interim results by mid 2018 IMO.
Let's say for a moment the registration trial is a success. Merck will fully step in then, IMO. Again, PD has said quite a few times that they have no intention of going to market alone and I trust him when he says that. Anyway, after success in melanoma, do you think Merck will wait for ONCS to take another 2 years for an additional indication and so on? I don't think so. I think FDA approval in melanoma combo will open the floodgates to multiple combo trials which ONCS will not be able to manage on its own. That's when the real reward may come in for investors, either through a buyout or a bigger collaboration. Of course the registration trial will need to produce statistically significant results. Hence the risk.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM